$TMO

Pettiti Gianluca sold $226K of TMO

Pettiti Gianluca (President & COO) sold 400 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $565.00 ($0.23M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pettiti Gianluca
Published Jul 28, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
high confidence
Mentioned
$TMO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

This provides confirmation of a planned insider sale, with limited implications for near-term valuation or operating outlook.

02

Market read

Traders may note the insider sale for sentiment, but the planned nature and modest dollar value suggest low fundamental impact.

03

What to watch

The sale is explicitly under a pre-arranged 10b5-1 plan, which often reduces interpretability versus discretionary sales.

Relevance 3/10Novelty 2/10Timing: after-hours filing timestamp on 2026-07-28

Background

The article is a SEC Form 4 disclosure of an insider open-market sale by Thermo Fisher’s President and COO.

Company-level read

Ticker impact

$TMONeutralHigh confidence
Context

Thermo Fisher insider Pettiti Gianluca, President and COO, sold 400 shares at $565 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and the disclosed sale size ($226k) is small relative to company scale.

Market effects

No direct sector read-through; this is company-specific insider liquidity.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be interpreted as reduced confidence, though this specific disclosure is not large or unscheduled.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • Pettiti Gianluca

    President and COO who sold 400 shares at $565 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOHighAI 8/10

Thermo Fisher Q3 Revenue Hits $12.14 Billion as Shares Touch Record $705 — BigGo Finance

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with shares reaching a record $705.79. Analysts raised target prices. Growth was driven by new products and AI initiatives, including a collaboration with Nvidia. The company also integrated Clario to expand clinical services. Revenue sources include lab consumables (52%) and high-growth areas like mass spectrometry and sequencing. AI and clinical data services are key focus areas for future growth.

$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

$TMOHighAI 8/10

Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth

Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% YoY, with organic growth of 6%. GAAP EPS rose 9% to $4.64, while adjusted EPS increased 15% to $6.68. The company attributed growth to innovation and strategic initiatives, including new product launches and partnerships. According to CEO Marc Casper, the results reflect strong execution and a proven growth strategy.